Search Results - "Van Moorselaar, J.A."

Refine Results
  1. 1
  2. 2

    Repeatability of Quantitative 18F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer by Jansen, Bernard HE, Cysouw, Matthijs CF, Vis, André N, van Moorselaar, Reindert JA, Voortman, Jens, Bodar, Yves JL, Schober, Patrick R, Hendrikse, N Harry, Hoekstra, Otto S, Boellaard, Ronald, Oprea-Lager, DE

    Published in The Journal of nuclear medicine (1978) (01-09-2020)
    “…Quantitative evaluation of radiolabeled prostate-specific membrane antigen (PSMA) PET scans may be used to monitor treatment response in patients with prostate…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5

    Bladder Cancer detection by urinary methylation markers GHSR/MAL: a validation study by Beijert, I. J., van den Burgt, Y., Hentschel, A. E., Bosschieter, J., Kauer, P. C., Lissenberg-Witte, B. I., van Moorselaar, R. J.A., Nieuwenhuijzen, J. A., Steenbergen, R. D.M.

    Published in World journal of urology (16-10-2024)
    “…Purpose Although cystoscopy is a reliable tool for detecting bladder cancer, it poses a high burden on patients and entails high costs. This highlights the…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

    Repeatability of Quantitative 18F-Fluoromethylcholine PET/CT Studies in Prostate Cancer by Oprea-Lager, Daniela E, Kramer, Gem, van de Ven, Peter M, van den Eertwegh, Alfons J M, van Moorselaar, Reindert J A, Schober, Patrick, Hoekstra, Otto S, Lammertsma, Adriaan A, Boellaard, Ronald

    Published in The Journal of nuclear medicine (1978) (01-05-2016)
    “…Repeatable quantification is essential when using (18)F-fluoromethylcholine PET/CT to monitor treatment response in prostate cancer. It has been shown that SUV…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13

    Optimization and validation of 18F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer by Luining, Wietske I., Oprea-Lager, Daniela E., Vis, André N., van Moorselaar, Reindert J. A., Knol, Remco J. J., Wondergem, Maurits, Boellaard, Ronald, Cysouw, Matthijs C. F.

    Published in PloS one (09-11-2023)
    “…Introduction Radiomics extracted from prostate-specific membrane antigen (PSMA)-PET modeled with machine learning (ML) may be used for prediction of disease…”
    Get full text
    Journal Article
  14. 14

    A protocol for urine collection and storage prior to DNA methylation analysis by Bosschieter, J, Bach, S, Bijnsdorp, I V, Segerink, L I, Rurup, W F, van Splunter, A P, Bahce, I, Novianti, P W, Kazemier, G, van Moorselaar, R J A, Steenbergen, R D M, Nieuwenhuijzen, J A

    Published in PloS one (24-08-2018)
    “…Urine poses an attractive non-invasive means for obtaining liquid biopsies for oncological diagnostics. Especially molecular analysis on urinary DNA is a rapid…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Repeatability of Quantitative 18 F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer by Jansen, Bernard H E, Cysouw, Matthijs C F, Vis, André N, van Moorselaar, Reindert J A, Voortman, Jens, Bodar, Yves J L, Schober, Patrick R, Hendrikse, N Harry, Hoekstra, Otto S, Boellaard, Ronald, Oprea-Lager, D E

    Published in Journal of Nuclear Medicine (01-09-2020)
    “…Quantitative evaluation of radiolabeled prostate-specific membrane antigen (PSMA) PET scans may be used to monitor treatment response in patients with prostate…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial by Janssen, J, Staal, F H E, Brouwer, C L, Langendijk, J A, de Jong, I J, van Moorselaar, R J A, Schuit, E, Verzijlbergen, J F, Smeenk, R J, Aluwini, S

    Published in BMC cancer (02-05-2022)
    “…More than 60% of oligo-recurrent prostate cancer (PCa) patients treated with metastasis-directed radiotherapy (MDRT) develop biochemical recurrence within…”
    Get full text
    Journal Article
  19. 19
  20. 20